Related Experiment Video
Updated: Sep 28, 2025

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
Published on: November 1, 2015
COVID-19 in patients with systemic lupus erythematosus: A systematic review
Xue-Lei Fu1, Yan Qian2, Xiao-Hong Jin2
1School of Medicine, 66479Nantong University, Nantong, Jiangsu, China.
Insights
Systemic lupus erythematosus (SLE) patients with COVID-19 experienced challenges in healthcare access and psychological distress. Hydroxychloroquine did not prevent COVID-19 in these patients.
Area of Science:
- Rheumatology
- Infectious Diseases
- Epidemiology
Background:
- Systemic lupus erythematosus (SLE) is an autoimmune disease.
- Coronavirus disease 2019 (COVID-19) is a global pandemic.
- Understanding the intersection of SLE and COVID-19 is crucial for patient care.
Purpose of the Study:
- To review the epidemiology of SLE and COVID-19.
- To identify clinical characteristics and treatment of COVID-19 in SLE patients.
- To assess the pandemic's impact on SLE patients' health and healthcare access.
Main Methods:
- Systematic literature review of PubMed.
- Inclusion criteria: human studies on COVID-19 in SLE patients, published Dec 2019-June 2021.
- 52 studies were included in the review.
Main Results:
- COVID-19 prevalence in SLE patients ranged from 0.0% to 18.1%; hospitalization rates were 0.24% to 10.6%.
- COVID-19 infection can mimic SLE flares.
- Hydroxychloroquine was ineffective for COVID-19 prevention; patients faced healthcare access issues, financial strain, and psychological distress.
Conclusions:
- The COVID-19 pandemic significantly impacted SLE patients' mental and physical health.
- Adequate healthcare access, containment policies, and psychological support are essential for managing SLE patients during pandemics.
- COVID-19 management in SLE requires careful consideration of disease-specific factors and patient well-being.
Abstract:
The objectives of the study were to review the articles to identify (a) the epidemiology of systemic lupus erythematosus (SLE) and coronavirus disease 2019 (COVID-19); (b) the clinical characteristics of SLE patients with COVID-19; (c) the treatment of COVID-19 in SLE patients; and (d) the impact of COVID-19 pandemic on SLE patients. PubMed was systematically reviewed for literature published from December 2019 to June 2021. Our search was limited to human studies, with language restriction of English. Studies were included if they reported COVID-19 in SLE patients. Our systematic review included 52 studies. The prevalence of COVID-19 infection ranged from 0.0% to 18.1% in SLE patients, and the hospitalisation rates ranged from 0.24% to 10.6%. COVID-19 infection is likely to mimic SLE flare. Hydroxychloroquine (HCQ) was ineffective in prevention of COVID-19, and SLE patients with COVID-19 faced difficulty in healthcare access, had financial constraints and suffered from psychological distress during the pandemic. The pandemic had a significant effect on mental and physical health. Adequate healthcare access, along with containment policies, social distancing measures and psychological nursing was required.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease III: Medical Management
Nephrotic Syndrome I : Introduction
Rheumatic Heart Disease I: Introduction
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune...

